# Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19

> **NCT06940765** · NA · WITHDRAWN · sponsor: **GID BIO, Inc.**

## Conditions studied

- Covid19

## Interventions

- **DEVICE:** GID SVF-2 Device System

## Key facts

- **NCT ID:** NCT06940765
- **Lead sponsor:** GID BIO, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No study sites established
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940765, "Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06940765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*